Edwards Lifesciences (NYSE:EW) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Edwards Lifesciences (NYSE:EW) released its earnings results on Wednesday. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01, Briefing.com reports. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The business had revenue of $1.63 billion for the quarter, compared to analyst estimates of $1.65 billion. During the same quarter in the previous year, the business earned $0.66 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 6.7% on a year-over-year basis. Edwards Lifesciences updated its Q3 guidance to $0.67-0.71 EPS and its Q3 2024 guidance to 0.670-0.710 EPS.

Edwards Lifesciences Stock Down 0.1 %

EW stock traded down $0.10 during trading on Wednesday, reaching $86.95. The stock had a trading volume of 3,277,317 shares, compared to its average volume of 3,397,984. Edwards Lifesciences has a one year low of $60.57 and a one year high of $96.12. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08. The company’s 50 day moving average is $89.18 and its two-hundred day moving average is $87.12. The company has a market capitalization of $52.40 billion, a price-to-earnings ratio of 37.29, a P/E/G ratio of 3.22 and a beta of 1.11.

Insiders Place Their Bets

In other news, CEO Bernard J. Zovighian acquired 580 shares of Edwards Lifesciences stock in a transaction on Monday, May 6th. The stock was acquired at an average cost of $85.74 per share, with a total value of $49,729.20. Following the transaction, the chief executive officer now owns 3,268 shares of the company’s stock, valued at approximately $280,198.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total value of $466,450.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at $4,378,659.44. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Bernard J. Zovighian bought 580 shares of the company’s stock in a transaction on Monday, May 6th. The stock was bought at an average price of $85.74 per share, for a total transaction of $49,729.20. Following the completion of the purchase, the chief executive officer now owns 3,268 shares of the company’s stock, valued at $280,198.32. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 81,099 shares of company stock valued at $7,003,553. Corporate insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on EW shares. StockNews.com upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Thursday, June 27th. Citigroup upped their price objective on shares of Edwards Lifesciences from $105.00 to $106.00 and gave the company a “buy” rating in a report on Wednesday, July 10th. The Goldman Sachs Group started coverage on shares of Edwards Lifesciences in a report on Thursday, May 30th. They set a “buy” rating and a $107.00 price objective on the stock. Royal Bank of Canada upped their price objective on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a report on Monday, April 15th. Finally, OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $96.13.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.